Use of Health Care Databases to Support Supplemental Indications of Approved Medications
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Importance: Manufacturers of US Food and Drug Administration-approved prescription drugs often apply for additional indications based on randomized clinical trials. Real-world database analyses on a medication's use and outcomes in routine settings of care might help to inform decision making regarding such supplemental indications. Objective: To examine whether longitudinal data from a health care database can support the results of a randomized clinical trial that led to a supplemental indication for telmisartan. Design, Setting, and Participants: This cohort study of patients newly prescribed telmisartan or ramipril used insurance claims data from a nationwide health care database from January 1, 2003, through September 30, 2009, to compare patient outcomes. This study replicated the inclusion and exclusion criteria used in the Ongoing Telmisartan Alone and in Combination with Ramipril Global End-point Trial (ONTARGET) and used propensity score matching to balance 74 patient characteristics. Data analysis was performed from February 15, 2017, to May 24, 2017. Exposures: Telmisartan use vs ramipril use. Main Outcomes and Measures: The primary outcome was a composite of myocardial infarction, stroke, or hospitalization for congestive heart failure. Results: Of the 640 951 patients included in the study, 48 053 were newly prescribed ramipril (mean [SD] age, 68.29 [9.52] years; 31 940 male [66.5%]) and 4665 were newly prescribed telmisartan (mean [SD] age, 69.43 [9.60] years; 2413 male [51.7%]). After propensity score matching, a total of 4665 patients were newly prescribed telmisartan (mean [SD] age, 69.43 [9.60] years; 2413 [51.7%]), and 4665 patients were newly prescribed ramipril (mean [SD] age, 69.36 [9.67] years; 2343 male [50.2%]). As seen in ONTARGET, the composite risk of stroke, myocardial infarction, and hospitalization for congestive heart failure was similar for the 2 medications (hazard ratio, 1.0; 95% CI, 0.9-1.1). In addition, the study found that telmisartan was associated with a substantially decreased risk of angioedema (hazard ratio, 0.1; 95% CI, 0.03-0.56) compared with ramipril. Conclusions and Relevance: Real-world data analyses of patients receiving routine care provided findings similar to those found in the randomized clinical trial that established telmisartan's supplemental indication. In certain situations, database studies may support supplemental applications for effectiveness for already approved medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Atypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959
Self-citationComparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies
Ioannidis, J. P. A. (2001) · JAMA · doi:10.1001/jama.286.7.821 · Cited by 919
Temple, R., & Ellenberg, S. S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00014 · Cited by 871
Anglemyer, A., Horvath, H. T., & Bero, L. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000034.pub2 · Cited by 534
Validity of diagnostic codes for acute stroke in administrative databases: a systematic review.
McCormick, N., Bhole, V., Lacaille, D., & Avina-Zubieta, J. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135834 · Cited by 414
Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334
Self-citationWhen and how can real world data analyses substitute for randomized controlled trials?
Franklin, J. M., & Schneeweiss, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.857 · Cited by 316
Validity of myocardial infarction diagnoses in administrative databases: a systematic review.
McCormick, N., Lacaille, D., Bhole, V., & Avina-Zubieta, J. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092286 · Cited by 262
A basic study design for expedited safety signal evaluation based on electronic healthcare data
Schneeweiss, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1926 · Cited by 255
Freemantle, N., Marston, L., Walters, K., Wood, J., Reynolds, M. R., & Petersen, I. (2013) · BMJ · doi:10.1136/bmj.f6409 · Cited by 211
Dahabreh, I. J., Sheldrick, R. C., Paulus, J. K., Chung, M., Varvarigou, V., Jafri, H., Rassen, J. A., Trikalinos, T. A., & Kitsios, G. D. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs114 · Cited by 204
Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: A Cohort Study
Gagne, J. J., Choudhry, N. K., Kesselheim, A. S., Polinski, J. M., Hutchins, D., Matlin, O. S., Brennan, T. A., Avorn, J., & Shrank, W. H. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2942 · Cited by 155
Self-citationNew “21st Century Cures” Legislation: Speed and Ease vs Science
Kesselheim, A. S., & Avorn, J. (2017) · JAMA · doi:10.1001/jama.2016.20640 · Cited by 93
Self-citation
Cited by
Patorno, E., Pawar, A., Franklin, J. M., Najafzadeh, M., Déruaz-Luyet, A., Brodovicz, K. G., Sambevski, S., Bessette, L. G., Santiago Ortiz, A. J., Kulldorff, M., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039177 · Cited by 215
Desai, R. J., Varma, V. R., Gerhard, T., Segal, J., Mahesri, M., Chin, K., Horton, D. B., Kim, S. C., Schneeweiss, S., & Thambisetty, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.6567 · Cited by 45
Suissa, K., Schneeweiss, S., Kim, D. W., & Patorno, E. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14367 · Cited by 41
Shao, S.-C., Su, Y.-C., Lai, E. C.-C., Chang, K.-C., Lee, C.-N., Hung, M.-J., Lai, C.-C., Huang, F.-C., & Hung, J.-H. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101318 · Cited by 40
Practice-Based Research Networks and the Mandate for Real-World Evidence
Hall-Lipsy, E., Barraza, L., & Robertson, C. (2018) · American Journal of Law & Medicine · doi:10.1177/0098858818789428 · Cited by 16
Metadata
- Authors
- Fralick, M., Kesselheim, A. S., Avorn, J., & Schneeweiss, S.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2018-01-01
- Volume
- 178
- Issue
- 1
- Pages
- 55
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2768945936
- Cited by
- 119
- References
- 19
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.